Mabwell’s Nectin-4 ADC shows cervical cancer activity, but can Phase 3 confirm survival benefit?
Updated 9MW2821 data support Nectin-4 as a target in cervical cancer, but Mabwell must prove that early response and survival signals outperform established ADC and immunotherapy options.